A Double-blind, Randomized, Phase III Study of Radiotherapy Combined With cetuXimab + Xevinapant Compared to Radiotherapy Combined With Cetuximab (Standard of Care) + Placebo in Patients With LA SCCHN, Unfit for High-dose Cisplatin
Latest Information Update: 16 May 2025
At a glance
- Drugs Cetuximab (Primary) ; Xevinapant (Primary)
- Indications Head and neck cancer; Hypopharyngeal cancer; Laryngeal cancer; Mouth neoplasm
- Focus Therapeutic Use
- Acronyms XXL_2022-01
Most Recent Events
- 09 May 2025 Status changed from completed to discontinued because of toxicity.
- 30 Apr 2025 Status changed from suspended to completed.
- 28 Jan 2025 Planned End Date changed from 1 Sep 2030 to 1 Sep 2035.